Even with Controlled LDL-Cholesterol, PCI Stent Patients Have Residual Inflammatory Risk

MedicalResearch.com Interview with:

Dr. George Dangas MD PhDProfessor of Medicine, CardiologyMount Sinai Health System

Dr. Dangas

Dr. George Dangas MD PhD
Professor of Medicine, Cardiology
Mount Sinai Health System

MedicalResearch.com: What is the background for this study?

Response: Widespread use of statins targeted to decrease levels of low density lipoprotein cholesterol (LDL-C) below 70mg/dL are recommended by guidelines. However, residual cholesterol risk may only be one part of the residual risk equation. Indeed, Biological inflammation has long been known as a pathophysiological mechanism of atherosclerosis and the recent CANTOS trial opened new therapeutic perspective by demonstrating that inflammation modulation via selective interleukin-1β inhibition could result in improved diagnosis in patients with coronary artery disease.

However, the prevalence and impact of a residual inflammatory biological syndrome in patients with controlled cholesterol risk is unclear.

MedicalResearch.com: What are the main findings?

Response: In the study we demonstrated that in patients undergoing PCI with controlled LDL-C at baseline, risk of adverse events remained high, despite the optimized medical treatment. The presence of persistent residual inflammatory risk (defined as hsCRP >2 mg/L in ≥2 serial measurement with at least 4 weeks delay) was present in a third of patients with controlled LDL-C at baseline and was independently associated with adverse events. 

MedicalResearch.com: What should readers take away from your report?

Response: The need for thorough control of the cholesterol risk in patients with coronary artery disease is now well implemented in the minds and practice of physician.

Our study shows the importance of the presence of persistent inflammatory risk overtime.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Our study warrants the realization of prospective therapeutic trials evaluating the impact of inflammation modulation, particularly, via selective inflammatory inhibition, in patients with coronary artery disease, with optimized medical treatment and controlled cholesterol risk.

Disclosures:

This study was performed in the Center for Interventional Cardiovascular research and clinical trial of the Zena and Michael A. Weiner Cardiovascular Institute of the Icahn School of Medecine.

Full author disclosures at the relevant publication.

Dr. Dangas reports nothing relevant to the subject of this interview. 

Citation:

Impact of Residual Inflammatory Risk in Patients With Low LDL-Cholesterol Undergoing Percutaneous Coronary Intervention: Insight From a Large Single-Center Registry

Paul GuedeneyBimmer ClaessenDeborah KalkmanMelissa AquinoSabato SorrentinoMoritz BlumGennaro GiustinoSerdar FarhanBirgitVogelSamantha SartoriGilles MontalescotJoseph SweenyJasonKovacicNitin BarmanGeorge DangasAnnapoorna KiniUsman BaberSamin SharmaRoxana Mehran

 

 

 

 

Mar 18, 2019 @ 12:59 pm

 

 

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.